A phase III double blinded study of early intervention after radical prostatectomy with androgen deprivation therapy with darolutamide versus placebo in men at highest risk of prostate cancer metastasis by genomic stratification (ERADICATE).
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Harvard University, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, Rutgers Cancer Institute, University of Maryland, Baltimore, Northwestern University, Endeavor Health, University of Chicago, 21st Century Oncology (United States), City Of Hope National Medical Center, University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center, Wake Forest University Health Sciences, Wake Forest University, Johns Hopkins University, Johns Hopkins Medicine, Sidney Kimmel Comprehensive Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4286295543